Latanoprost Eye Drops Manufacturer in India

Latanoprost 0.005% offers the highest IOP-lowering efficacy among all topical antiglaucoma agents — reducing IOP by 25–35% from baseline — combined with once-daily evening dosing (the most compliant regimen possible). It works by increasing uveoscleral aqueous outflow through the FP prostaglandin receptor, a different mechanism from beta-blockers, making it effective even in patients where Timolol is insufficient or contraindicated.

Latanoprost 0.005% requires cold chain storage at 2–8°C (refrigerated) before opening. After opening, the bottle is stable at room temperature (below 25°C) for 4 weeks. 9M India manages cold chain manufacture, storage and dispatch with documented temperature monitoring records for every batch and shipment. Cold chain documentation is provided as part of the batch CoA and export documentation package.

Latanoprost has a distinctive and well-documented side effect profile from its prostaglandin mechanism: iris colour change (increased brown pigmentation — particularly in hazel/green eyes), eyelash growth and darkening (hypertrichosis), periorbital skin darkening, and deepening of the upper lid sulcus. These are permanent changes with long-term use. Prescribers inform patients — particularly those using drops in one eye only where asymmetry may be visible.

Latanoprost is first-line or adjunct therapy for open-angle glaucoma and ocular hypertension — the most common forms of glaucoma. It is particularly valuable as it can be used in patients with asthma or COPD where beta-blockers like Timolol are contraindicated. It is also used in normal tension glaucoma where IOP lowering beyond normal range has been shown to reduce progression. It is not the agent of choice for acute angle-closure glaucoma.

Yes. Latanoprost is increasingly included in national essential medicine lists and glaucoma management guidelines as first-line therapy. 9M India manufactures Latanoprost for institutional and government programme supply with full cold chain documentation, CoPP and batch CoA. Please contact our export team with programme volume and cold chain infrastructure requirements.

Yes. 9M India manufactures Latanoprost 0.005% + Timolol 0.5% fixed-dose combination eye drops — combining the most effective prostaglandin analogue with the most established beta-blocker in a single once-daily formulation. This combination provides additive IOP lowering (typically 30–40% reduction) with maximum convenience for patients requiring dual therapy.

Documentation available includes WHO-GMP Certificate, DCGI Manufacturing Licence, CoPP, batch- wise CoA (sterility, particulate matter, pH, assay, cold chain temperature records), ICH Zone IVb stability data (including cold chain stability), and CTD/ACTD dossiers on request. Cold chain documentation covering manufacture, storage and dispatch is included as standard for Latanoprost export.